Sapient Capital LLC Buys New Shares in Exact Sciences Co. (NASDAQ:EXAS)

Sapient Capital LLC purchased a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,816 shares of the medical research company’s stock, valued at approximately $282,000.

A number of other large investors have also recently bought and sold shares of EXAS. KB Financial Partners LLC acquired a new stake in Exact Sciences during the second quarter worth approximately $32,000. Wolff Wiese Magana LLC grew its holdings in Exact Sciences by 459.5% in the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after purchasing an additional 340 shares during the period. BluePath Capital Management LLC bought a new stake in Exact Sciences in the third quarter valued at $33,000. Coppell Advisory Solutions LLC acquired a new position in shares of Exact Sciences during the second quarter valued at about $46,000. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Exact Sciences during the 3rd quarter worth about $34,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Exact Sciences

In other news, insider Jacob A. Orville sold 966 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total transaction of $59,341.38. Following the completion of the transaction, the insider now owns 7,488 shares in the company, valued at approximately $459,987.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Exact Sciences news, Director D Scott Coward sold 1,376 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total transaction of $84,527.68. Following the sale, the director now owns 41,580 shares of the company’s stock, valued at approximately $2,554,259.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jacob A. Orville sold 966 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $59,341.38. Following the completion of the transaction, the insider now directly owns 7,488 shares of the company’s stock, valued at $459,987.84. The disclosure for this sale can be found here. Insiders have sold a total of 69,113 shares of company stock worth $4,165,273 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Exact Sciences Price Performance

EXAS opened at $65.35 on Tuesday. The firm has a market cap of $11.86 billion, a P/E ratio of -57.32 and a beta of 1.25. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32. Exact Sciences Co. has a fifty-two week low of $56.05 and a fifty-two week high of $100.77. The firm has a 50-day moving average of $63.33 and a 200 day moving average of $65.16.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The company had revenue of $646.89 million during the quarter, compared to analyst estimates of $638.83 million. During the same quarter last year, the business posted ($0.72) EPS. Exact Sciences’s quarterly revenue was up 17.0% compared to the same quarter last year. On average, research analysts expect that Exact Sciences Co. will post -0.86 EPS for the current year.

Analyst Ratings Changes

EXAS has been the subject of a number of research analyst reports. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Benchmark upgraded shares of Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target for the company in a research note on Tuesday, January 2nd. TheStreet lowered shares of Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Canaccord Genuity Group cut their price target on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Finally, Citigroup reissued a “buy” rating and issued a $100.00 price objective on shares of Exact Sciences in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $97.44.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.